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Abstract
The aim of this paper is to provide a systematic review of the literature examining the
epidemiology, outcome, and treatment of patients with bipolar disorder and co-occurring
substance use disorders (SUDs). Articles for this review were initially selected via a comprehensive
Medline search and further studies were obtained from the references in these articles. Given the
lack of research in this field, all relevant studies except case reports were included.
Prior epidemiological research has consistently shown that substance use disorders (SUDs) are
extremely common in bipolar I and II disorders. The lifetime prevalence of SUDs is at least 40% in
bipolar I patients. Alcohol and cannabis are the substances most often abused, followed by cocaine
and then opioids. Research has consistently shown that co-occurring SUDs are correlated with
negative effects on illness outcome including more frequent and prolonged affective episodes,
decreased compliance with treatment, a lower quality of life, and increased suicidal behavior.
Recent research on the causal relationship between the two disorders suggests that a subgroup of
bipolar patients may develop a relatively milder form of affective illness that is expressed only after
extended exposure to alcohol abuse.
There has been very little treatment research specifically targeting this population. Three open
label medication trials provide limited evidence that quetiapine, aripiprazole, and lamotrigine may
be effective in treating affective and substance use symptoms in bipolar patients with cocaine
dependence and that aripiprazole may also be helpful in patients with alcohol use disorders. The
two placebo controlled trials to date suggest that valproate given as an adjunct to lithium in bipolar
patients with co-occurring alcohol dependence improves both mood and alcohol use symptoms
and that lithium treatment in bipolar adolescents improves mood and SUD symptoms.
Given the high rate of SUD co-occurrence, more research investigating treatments in this
population is needed. Specifically, double blind placebo controlled trials are needed to establish the
effectiveness of medications found to be efficacious in open label treatments. New research also
needs to be conducted on medications found to treat either bipolar disorder or a SUD in isolation.
In addition, it may be advisable to consider including patients with prior SUDs in clinical trials for
new medications in bipolar disorder.
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Introduction
Bipolar I and II disorders are common and serious mental
illnesses that have been reported to occur in approxi-
mately 1–3% [1,2] and 3–5% [3,4] of the US population
respectively. Bipolar disorders are often complicated by
co-occurring substance use disorders (SUDs). The aim of
this paper is to provide a systematic review of the litera-
ture examining the epidemiology, outcome, and treat-
ment of patients with bipolar disorder and co-occurring
substance use disorders (SUDs). Articles for this review
were initially selected via a comprehensive Medline search
and further studies were obtained from the references in
these articles. Given the lack of research in this field, all
relevant studies except case reports were included.
The most thorough research in this field comes from epi-
demiological studies. Several large and well designed
studies have consistently found high rates of co-occurring
SUDs in bipolar disorder [2,5-9]. Several smaller studies
have also added epidemiological information in specific
populations [10-12]. Research in the last 2 decades has
also focused on examining the effects of SUDs on the ill-
ness course of bipolar disorder [13-24]. Some recent stud-
ies also examined the sequence of onset of the two
conditions to address questions of causality [14,18,19].
Finally, only a small number of studies have examined
specific treatments in bipolar patients with SUDs [25-34].
Epidemiology
Several studies investigated the prevalence of co-occurring
SUDs in bipolar I and II disorders [5-10,35]. The largest
study was conducted as part of the National Epidemio-
logic Survey on Alcohol and Related Conditions
(NESARC) [2]. The NESARC examined the prevalence and
co-occurrence of DSM-IV substance, mood, and anxiety
disorders in a representative sample of 43,093 respond-
ents in the US. In subjects with bipolar I disorder, there
was a 58% lifetime prevalence of co-occurring alcohol use
disorders and a 38% lifetime prevalence of any drug use
disorder. Another large survey was conducted as part of
the National Institutes of Mental Health Epidemiologic
Catchment Area Program [5]. The prevalence of mental
illness and SUDs was obtained from 20,291 persons from
community and institutional settings. Among patients
with bipolar type I disorder, 61% had a lifetime history of
any drug or alcohol use disorder (46% had a lifetime his-
tory of an alcohol use disorder and 41% had a lifetime
history of drug abuse or dependence) [5]. In patients with
bipolar Type II disorder, 48% had a lifetime history of any
drug or alcohol use disorder (39% had a lifetime history
of an alcohol use disorder and 21% had a lifetime history
of drug abuse or dependence). Among psychiatric ill-
nesses, only anti-social personality disorder had a higher
lifetime prevalence rate of any SUD (17% for the general
population, 47% for schizophrenia, 27.2% for major
depressive disorder, and 84% for anti-social personality
disorder).
In another large study, Cassidy et al. [6] surveyed 392
patients who meet DSM-IIIR criteria for bipolar disorder
in a mixed or manic episode. They found a lifetime prev-
alence of 48.5% for alcohol abuse, 24.2% for cocaine
abuse, 4.6% for opioid abuse, and 36% for cannabis
abuse. The point prevalence of SUDs at the time of the
interview was 28.5% for alcohol abuse, 10.2% for cocaine
abuse, 1.0% for opioid abuse, and 22.2% for cannabis
abuse. McElroy et al. [7] evaluated 239 bipolar I and 49
bipolar II outpatients for any Axis I comorbidity. In bipo-
lar I patients, the lifetime prevalence was 36, 10, 40, and
8 % for alcohol, cocaine, cannabis, and opioid use disor-
ders respectively. In bipolar II patients, the lifetime preva-
lence was 22, 4, 10, and 0 % for alcohol, cocaine,
cannabis, and opioid use disorders respectively. Chen-
gappa et al. [35] interviewed 71 bipolar I and 18 bipolar
II patients from a voluntary case registry of bipolar disor-
der. For bipolar I patients, the lifetime prevalence was
57.8, 11.3, 19.7, and 5.6 % for alcohol, cocaine, cannabis,
and opioid use disorders respectively. For bipolar II
patients, the lifetime prevalence was 38.9, 5.6, 5.6, and 0
% for alcohol, cocaine, cannabis, and opioid use disorders
respectively.
Data regarding co-occurring SUDs and bipolar disorder
have also been obtained from the two major first episode
mania studies [8,9]. In The University of Cincinnati First-
Episode Mania Study [8,14,15,36,37], the authors fol-
lowed over a hundred patients who initially presented
with a first manic or mixed episode and met DSM-IV cri-
teria for bipolar type I disorder. The lifetime prevalence of
alcohol and cannabis use disorders was 42% and 46%,
respectively, in the 144 bipolar I patients studied [14,15].
Patel et al. [37] also used these data to examine differences
in 103 early onset (age 12 to 17) and 58 typical onset (age
20 to 30) bipolar type I patients. Patients in the typical
onset group were more likely to have a SUD (41%) com-
pared to patients in the early onset group (24%). How-
ever, this finding may have been partly explained by the
higher percentage of mixed episode presentations in the
early onset group (67%) compared to the typical onset
group (29%), because mixed patients were significantly
less likely to have any co-occurring SUD.
The McLean-Harvard First-Episode Mania Study followed
over a hundred patients for 2–4 years who initially pre-
sented with a first manic or mixed episode and met DSM-
IV criteria for bipolar type I disorder [13]. Baethge et al. [9]
used data from the first 112 patients from this study to
examine co-morbid SUDs. All patients met DSM-IV crite-
ria for bipolar type I disorder and presented to McLean
hospital with a manic or mixed episode. The patients wereSubstance Abuse Treatment, Prevention, and Policy 2007, 2:29 http://www.substanceabusepolicy.com/content/2/1/29
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followed for up to two years. At the index manic episode,
thirty-seven (33%) of the patients were found to have a
SUD with 22 patients using only one substance. The most
common SUDs were alcohol abuse and dependence, fol-
lowed by cannabis and then cocaine use disorders. Anxi-
ety disorders were also found to be more frequent in
patients with a SUD (30% vs. 13%). At the end of the 24
month follow up period, 31 out of the 80 remaining
patients (39%) had a current SUD.
Two recent studies examined co-morbid SUDs and bipo-
lar disorder in the Veterans Affairs (VA) hospital popula-
tion [10,11]. Both studies used patient data from the
Veterans Affairs (VA) Cooperative Study #450 (Reducing
the Efficacy-Effectiveness Gap in Bipolar Disorder)
[38,39]. Bauer et al. [10] examined 328 inpatients from 11
VA hospitals with bipolar I or II disorder from this study.
Bipolar I and II patients were not analyzed separately but
were grouped together for all prevalence calculations.
They found a 33.8% current and 72.3% lifetime preva-
lence of a SUD. Alcohol use disorders had the highest life-
time prevalence (61.9%), followed by cannabis use
disorders (22.6%), cocaine use disorders (19.5%), and
then opioid use disorders (8.5%). Alcohol use disorders
also had the highest point prevalence rates (25.6%), fol-
lowed by cocaine use disorders (6.7%), cannabis use dis-
orders (6.1%), and opioid use disorders (2.7%).
Kilbourne et al. [11] used the VA study data to examine
differences in bipolar type I disorder among minority
populations. They examined 330 inpatients: 249 (76%)
Caucasian; 47 (14%) African American; 26 (5%) His-
panic; 12 (4%) Native American; and 5 (1%) Asian/
Pacific-Islander or other. Among the patients, 286 were
diagnosed with bipolar type I disorder, 40 with bipolar
type II disorder, and 1 with bipolar disorder NOS, and the
three patient groups were combined in the analysis.
Minority bipolar patients had a significantly higher
number of cocaine use disorders (OR 2.2) and current
alcohol abuse disorders (OR 1.8) compared to Caucasian
patients. Among the minority groups, the only difference
found was that cocaine use was significantly higher in
African American patients (29%) compared with all other
minorities (6%).
One recent study provided prevalence data for co-occur-
ring SUDs in rapid-cycling bipolar patients. In this pro-
spective study, Kupka et al. [12] followed 410 bipolar I,
104 bipolar II, and 16 bipolar disorder NOS patients over
one year. Among these patients, 206 met the DSM-IV cri-
teria for the rapid-cycling specifier. Rapid-cycling patients
were significantly more likely to have a past diagnosis of
drug (but not alcohol) abuse (27.3%) than non rapid-
cycling patients (17.2%).
Outcome
Recent research has increasingly focused on examining
the effects that co-occurring SUDs have on illness course
in bipolar disorder [13-24]. Many of the studies men-
tioned previously also addressed outcome questions,
including the two major first episode mania studies
[8,13]. Using data from the McLean Harvard First-Episode
Mania Study [40,41], Tohen et al. [13] examined the clin-
ical characteristics of 173 bipolar I patients who were fol-
lowed for up to 5 years. They found that co-morbid SUDs
were associated with increased episodes of depression.
Strakowski et al. [8] and Strakowski et al. [36] examined
the first 50 and 109 bipolar I patients respectively from
The University of Cincinnati First-Episode Mania Study.
Bipolar patients with co-morbid SUDs had increased
treatment noncompliance compared to bipolar patients
without any co-occurring SUD. Co-morbid SUDs had
other direct negative effects even after adjusting for non-
compliance (which was associated with poorer outcome),
including a delayed onset of symptomatic recovery. In
addition, alcohol abuse was positively correlated with the
duration of depression, and the duration of cannabis
abuse was positively correlated with the duration of
mania.
Two more recent studies have used the University of
Cincinnati data to examine the outcome of alcohol and
cannabis use disorders on bipolar disorder [14,15]. These
two studies attempted to investigate questions of causality
(i.e. whether SUDs increase the risk of developing bipolar
disorder or vice versa) by examining the sequence of onset
of the two conditions. Although many patients had both
alcohol and cannabis use disorders, each disorder had
independent effects on the outcome of bipolar disorder
[14,15]. Strakowski et al. [14] examined 27 bipolar I sub-
jects in which the onset of an alcohol use disorder pre-
ceded the onset of bipolar disorder (Alcohol First) and 33
subjects in whom the bipolar disorder preceded or was
concurrent with the onset of the alcohol use disorder
(Bipolar First). The Bipolar First patients had more affec-
tive symptoms, earlier onset of bipolar disorder, and a
slower recovery of affective symptoms compared to the
Alcohol First patients. These results suggest that the Alco-
hol First patients may form a subgroup of bipolar patients
that develop a relatively milder form of affective illness
that is expressed only after extended exposure to alcohol
abuse. Strakowski et al. [15] examined 33 bipolar I sub-
jects in which the onset of a cannabis use disorder pre-
ceded the onset of bipolar disorder (Cannabis First) and
36 subjects in whom the bipolar disorder preceded or was
concurrent with the onset of the alcohol use disorder
(Bipolar First). The Cannabis First group did not differ
from the Bipolar First group in terms of affective symp-
toms or age of onset of bipolar disorder. The Cannabis
First group did show significantly higher rate of and moreSubstance Abuse Treatment, Prevention, and Policy 2007, 2:29 http://www.substanceabusepolicy.com/content/2/1/29
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rapid recovery from affective episodes than the Bipolar
First group. However, these differences did not remain
after adjusting for potential mediator variables (including
gender and age of onset, both of which were associated
with time of recovery).
Three studies have used data from the Systematic Treat-
ment Enhancement Program for Bipolar Disorder (STEP-
BP) [42] to examine outcome in bipolar disorder with co-
occurring SUDs [16-18]. Weiss et al. [16] examined the
clinical characteristics of the first 1000 patients to enter
STEP-BP, of which 105 had a current SUD, 332 had a past
SUD, and 480 had no history of a SUD. Most (> 70%)
patients met DSM-IV criteria for bipolar I disorder while
the remainder of the patients were diagnosed with bipolar
II, bipolar NOS, cyclothymia, or schizoaffective disorder.
Compared with patients with no SUD, patients with a cur-
rent or past SUD had a lower quality of life as measured
by the Longitudinal Interval Follow-Up Evaluation-Range
of Impaired Functioning Tool (LIFE-RIFT) and the quality
of Life Enjoyment and Satisfaction Questionnaire.
Patients with a current or past SUD also had a higher
number of lifetime suicide attempts and were less likely to
have a clinical status of recovering or recovered. Martinez
et al. [17] analyzed the STEP-BP data and found that SUDs
are significantly associated with all serious adverse events.
Serious adverse events were defined as any event that "is
fatal, life-threatening, disabling or incapacitating, requires
or prolongs hospital stay, is a congenital anomaly in the
offspring of a participant, or jeopardizes the participant or
necessitates and intervention to prevent one of the afore-
mentioned outcomes". Finally, Fossey et al. [18] used the
first 1000 patients of the STEP-BP study to look at the
validity of the distinction between primary and secondary
SUD. A primary SUD precedes the onset of the bipolar dis-
order while a secondary SUD occurs after the onset of
bipolar disorder. Of the 1000 patients, 116 had a primary
SUD and 275 had a secondary SUD. They found that
patients with a secondary SUD had fewer days of
euthymia, more episodes of mania and depression, and a
more suicide attempts than patients with a primary SUD.
However, they found that these distinctions could all be
explained by age at onset of bipolar disorder and therefore
concluded that the primary secondary distinction is not
valid. However, this study did not report how it defined
age at onset, and moreover, many patients had been ill
with both disorders for many years, making these results
difficult to compare to first-episode studies. Winokur et al.
[19] also examined the distinction between a primary and
secondary SUD in bipolar disorder. They studied 30 bipo-
lar patients (type unspecified) with primary alcohol use
disorder and 34 bipolar patients with secondary alcohol
use disorder. They found that the alcohol use disorder was
significantly more likely to remit in the secondary SUD
and patients with a primary SUD had significantly fewer
episodes of affective episodes. Therefore they suggested
that bipolar disorder associated with a primary SUD was
a less severe form of illness that may require an alcohol
use disorder to manifest.
In addition to the Weiss et al. study [16], three other out-
come studies found that suicidal behavior is more likely
in bipolar patients with SUDs than in those without [20-
22]. Dalton et al. [20] examined 336 bipolar I and II and
schizoaffective disorder (bipolar type) patients who were
originally enrolled in a genetics study. They found that a
history of a drug use disorder increased the risk twofold
(OR = 2.1) for lifetime suicide attempts compared to
patients without a history of SUD. They found no differ-
ences in rates of suicide attempts in patients with co-
occurring alcohol use disorders compared to those with-
out. In a retrospective study, Goldberg et al. [21] exam-
ined 100 patients diagnosed with dysphoric mania
(patients were diagnosed with acute mania according to
the DSM-IIIR and had ≥ 2 prominent concomitant depres-
sive symptoms). Patients with a history of an alcohol use
disorder were significantly more likely to report suicidal
ideation. Swann et al. [22] examined 48 inpatients with
bipolar disorder (type unspecified) in a cross-sectional
study of impulsivity and suicidal behavior in bipolar dis-
order. They found that a history of alcohol abuse was
associated with an increased probability of a suicide
attempt. The authors suggested this behavior could be
explained by increased impulsivity measures in patients
with a history of alcohol abuse.
Two smaller prospective trials have examined outcome
[23,24]. Tohen et al. [23] followed 75 patients diagnosed
with bipolar disorder, manic type according to the DSM-
III, for 4 years to investigate outcome after recovering
from an episode of mania. A history of an alcohol use dis-
order was associated with an unfavorable outcome as
defined by lower residential and occupational status.
Singh et al. [24] examined 80 patients diagnosed with
bipolar affective disorder using the International Classifi-
cation of Diseases 10 (ICD-10). Half of the patients were
also diagnosed with a co-occurring SUD. The bipolar
patients with SUDs scored significantly lower on the
World Health Organization Quality of Life (WHO-QOL)
scale.
Finally, in a large chart review study, Feinman and Dun-
ner [43] examined clinical characteristics and outcome
measures in 188 bipolar I, II, NOS, and cyclothymic
patients. One hundred and three patients had no history
of SUDs (primary), 35 patients had a SUD which devel-
oped after the bipolar illness (complicated), and 50
patients had the onset of bipolar disorder after a SUD
(secondary). The complicated group had the highest
number of attempted suicides, and both the complicatedSubstance Abuse Treatment, Prevention, and Policy 2007, 2:29 http://www.substanceabusepolicy.com/content/2/1/29
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and secondary group had significantly increased scores on
the Hamilton Anxiety and Beck Depression rating scales.
Treatment
Although bipolar disorder is complicated by SUDs in
nearly half the total number of cases, there is a scarcity of
research examining treatment in this specific population.
In addition, most of these studies used open label designs
and therefore should not be used to guide treatment [25-
27,29,30,44,45]. Instead, successful open label studies
should guide further research and be replicated using dou-
ble-blind placebo-controlled studies. This problem is
compounded because substance abuse is often an exclu-
sionary criterion in many double-blind placebo-control-
led bipolar treatments studies [22]. Given these
limitations, Kosten and Kosten [31] reviewed medication
strategies in bipolar patients with co-occurring SUDs.
They suggested carbamazepine and valproate should be
considered in these populations because both medica-
tions may have some benefit in patients with alcohol use
disorders and valproate may also be effective in prevent-
ing cocaine relapse.
Two open label studies measuring responsiveness to lith-
ium in bipolar patients found that co-occurring substance
abuse was a predictor of a poor outcome [29,30]. O'Con-
nell et al. [29] followed 248 patients diagnosed with bipo-
lar disorder according to the DSM-III for at least one year.
Co-occurring SUDs were associated with a lower Global
Assessment Scale (GAS) score. Kusalic and Engelsmann
[30] followed 29 patients diagnosed with bipolar disorder
according to the DSM-III for up to two years. Co-occurring
SUDs were a strong predictor of non-response. In contrast
to O'Connell et al [29] and Kusalic and Engelsmann [30],
Geller et al. [28] found that lithium may be useful in bipo-
lar adolescents with a secondary SUD. They studied lith-
ium versus placebo in 25 adolescents with bipolar
disorder (12 with bipolar I, 5 with bipolar II, and 8 with
major depressive disorder in the presence of future predic-
tors for bipolar disorder) and a co-occurring SUD
(dependence on drugs or alcohol). Patients in the lithium
group had significantly greater improvement in both the
affective symptoms and the SUD.
Salloum and colleagues have studied the effectiveness of
valproate maintenance in bipolar type I patients with co-
occurring alcohol [25] and cocaine dependence [46]. In
the first study, a double-blind placebo-controlled trial,
Salloum et al. [46] studied the effectiveness of treatment
as usual (lithium) or lithium plus valproate in patients
with co-occurring alcohol dependence. Subjects were fol-
lowed for 24 weeks. Fifty nine patients who met DSM-IV
criteria for current alcohol dependence and an acute epi-
sode of bipolar I disorder (either a manic, mixed or
depressive episode) participated in the study. The HDRS
and the Bech-Rafaelsen Mania Scale (BRMS) were used as
outcome measures of affect while the number of heavy
drinking days and the number of drinks per heavy drink-
ing day were used to assess alcohol use. The valproate
group had significantly lower numbers of heavy drinking
days. The valproate group also had fewer drinks per heavy
drinking day when medication adherence was added as a
covariate. Both of these improved outcomes were corre-
lated with higher valproate serum levels. There was no dif-
ference in the two groups on the HDRS or BRMS. The
second study was an open label trial of divalproex in
seven subjects with co-occurring cocaine dependence and
an alcohol use disorder [25]. Subjects were started on
divalproex and followed for 8 weeks. The authors found a
significant increase in number of days abstinent from
cocaine; a significant decrease in money spent on cocaine;
a significant improvement in the Addition Severity Index
drug severity index; and significant decreases in affective
symptoms as measured by the HAMD and BRMS.
Brown and colleagues have studied multiple medications
for use in bipolar patients with co-occurring SUDs
[26,27,44,45]. Brown et al. [27] studied the effectiveness
of aripiprazole treatment in an open-label study of bipo-
lar type I patients suffering an acute mood episode with a
co-occurring SUD. Twenty patients were enrolled in the
study; 18 subjects met DSM-IV criteria for bipolar type I
disorder; 1 met the criteria for bipolar II disorder; and 1
met the criteria for schizoaffective disorder, bipolar type.
Eleven patients were experiencing a depressive episode, 6
a mixed episode, 4 a manic episode, and one patient did
not meet criteria for a current mood state. All subjects had
at least one co-occurring SUD which included alcohol
dependence (N = 17), cannabis use disorders (N = 3),
cocaine use disorders (N = 10), and opioid dependence
(N = 3). All patients were switched from their previous
treatment to aripiprazole and followed over 12 weeks.
There was significant improvement in baseline-to-exit
HDRS, YMRS, and BPRS scores at the end of the trial. In
addition, patients with alcohol dependence had a signifi-
cant decrease in dollars spent on alcohol and alcohol crav-
ing, and patients with cocaine dependence had a
significant decrease in cocaine craving but not in cocaine
use.
Brown et al. [45] examined the effectiveness of lamotrig-
ine in an open label study with bipolar outpatients with
co-occurring cocaine dependence. The study included 22
bipolar I, 7 bipolar II, and 1 bipolar not otherwise speci-
fied (NOS) subjects. Lamotrigine was titrated up to 300
mg/day and patients were followed for 12 weeks either as
an add on or as a monotherapy if the patient was not tak-
ing any other medications. Ten patients were experiencing
a depressive episode, 7 a mixed episode, 9 a manic epi-
sode, and three patients did not meet criteria for a currentSubstance Abuse Treatment, Prevention, and Policy 2007, 2:29 http://www.substanceabusepolicy.com/content/2/1/29
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mood state. In addition to cocaine dependence, many
subjects also had co-occurring alcohol and other sub-
stance use disorders. At the end of the study patients had
significantly improved HDRS, YMRS, and BPRS. Cocaine
cravings were significantly decreased as measured by the
CCQ but there was no significant decrease in the dollar
amount spent on cocaine.
Brown et al. [26] studied quetiapine add on therapy in a
12 week open label study of 14 bipolar type I and 3 bipo-
lar type II patients with co-occurring cocaine dependence.
At the end of the study there was a significant improve-
ment in scores on the Hamilton Depressive Rating Scale
(HDRS), Young Mania Rating Scale (YMRS), Brief Psychi-
atric Rating Scale (BPRS), and Cocaine Craving Question-
naire (CCQ). However, there was no significant change in
dollars spent on cocaine, duration of cocaine use, and
positive urine drug screens. Finally, Brown et al. [44] stud-
ied Naltrexone in an open label study in 34 bipolar out-
patients with co-occurring alcohol dependence.
Natltrexone was added as an adjunct to the patients exist-
ing psychotropic medications which included a variety of
anti-depressants and mood stabilizers. The patients
showed significant improvement in HAMD and YMRS
scores and had significant decreases in alcohol use and
craving.
Three studies have examined the effectiveness of psycho-
therapy as an adjunct to medications [33,34,47]. Drake et
al. [47] examined the effectiveness of integrated dual dis-
order treatment in the state mental health system in bipo-
lar patients with co-occurring SUDs. They followed 51
bipolar patients (type not specified) in the state mental
health system for three years. Although there were few
clinically significant improvements in psychiatric symp-
toms, there were significant clinical improvements in the
substance abuse. Nearly two-thirds of the patients were in
full remission from their SUD at 3 years. However, this
study was limited by the lack of a comparison group.
Schmitz et al. [33] randomly assigned 46 bipolar outpa-
tients (type unspecified) to medication or medication
plus cognitive behavioral therapy for 12 weeks. Patients in
the therapy group reported significantly fewer days of
manic or depressive symptoms. There were no differences
in measures of drug and alcohol use or medication com-
pliance. Weiss et al. [34] compared integrated group ther-
apy versus group drug counseling in 62 bipolar patients
(50 with bipolar I, 10 with bipolar II, and 2 with bipolar
NOS). All patients had an alcohol or drug use disorder
(dependence). Patients in the integrated group therapy
treatment had significantly fewer days of substance use
but had significantly more affective symptoms.
Finally, treatment is further complicated because the qual-
ity of care for SUDs is diminished in patients with bipolar
disorder. Kilbourne et al. [48] examined 1,559 patients
with mental illness and co-occurring SUD from the
Nation Patient Care Database. The quality of the sub-
stance abuse treatment was assessed by measures of iden-
tification, initiation, and engagement of the SUD. Bipolar
patients (23 percent of the total) were found to be less
likely to initiate or continue treatment for a SUD com-
pared to those with schizophrenia and schizoaffective dis-
order.
Conclusion
Research has consistently shown that patients with bipo-
lar I and II disorder have an extremely high rate of co-
occurring SUDs (see Table 1). Among the bipolar spec-
trum, bipolar type I has consistently been shown to have
higher rates of co-occurring SUDs than bipolar type II,
bipolar NOS, and cyclothymic disorder [5-10,35]. Based
on multiple large prior studies it can be conservatively
estimated that bipolar I patients have at least a 40% life-
time prevalence of alcohol and other drug use disorders
(with bipolar II patients having at least a 20% lifetime
prevalence) [5-10,35]. The highest rate of SUDs was
found in the VA population at 61.9 % lifetime prevalence
of alcohol use disorders [10]. Alcohol and cannabis are
the substances most often abused, followed by cocaine
and then opioids [5-7], likely reflecting the general avail-
ability of these compounds, rather that diagnosis-specific
selection.
Research examining the effect of SUDs on illness course
has been just as consistent and has clearly shown that co-
occurring SUDs are associated with significant negative
effects on outcome [8,13,16]. Patients with co-occurring
SUDs have more and prolonged affective episodes and are
less compliant with treatment. Four separate studies have
also linked co-occurring SUDs with increased suicidal
behavior [16,20-22]. Finally, patients with co-occurring
SUDs have a lower overall quality of life compared to
bipolar patients without SUDs [16]. However, a major
limitation of these studies is the inability to address the
causal relationship between the poor outcome and the
SUD. Co-occurring SUDs may by contributing to the neg-
ative outcome: Alternatively, patients with poor outcome
may have a more severe form of the disorder that also
places them at risk for SUDs.
An interesting new line of research is examining whether
patients who develop bipolar disorder after prolonged
substance use may represent a subtype of bipolar disorder
[14,18,19]. Fossey et al. [18] provided evidence that the
effects of SUDs on bipolar disorder can be explained in
terms of an earlier age of onset. However, Strakowski et al.
[14] showed effects of alcohol use independent of age at
onset. Strakowski et al [14] and Winokur et al [19] also
found evidence that bipolar disorder that presents after aSubstance Abuse Treatment, Prevention, and Policy 2007, 2:29 http://www.substanceabusepolicy.com/content/2/1/29
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SUD may form a subgroup of bipolar patients that
develop a relatively milder form of affective illness that is
expressed only after extended exposure to alcohol abuse.
The scarce research regarding effective treatment in this
patient population is far from conclusive. Most of the
treatment studies were limited by an open label design
and small numbers (see Table 2). The situation is further
complicated because many placebo controlled clinical tri-
als of bipolar disorder exclude patients with co-occurring
SUDs. The two placebo controlled trial support the addi-
tion of valproate to lithium in bipolar patients with co-
occurring alcohol dependence [25] and lithium treatment
in bipolar adolescents with co-occurring SUDs [28]. Open
label trials have provided limited evidence that quetiapine
[26], aripiprazole [27], and lamotrigine [45] may be effec-
tive in treating affective and substance use symptoms in
bipolar patients with cocaine dependence and aripipra-
zole may also be effective in patients with alcohol use dis-
orders.
The research reviewed highlights the importance of co-
occurring SUDs in bipolar disorders. Nearly half of the
bipolar patients a physician treats will also have a SUD.
Outcome research has revealed that the SUD will have sig-
nificant adverse effects on illness outcome. Yet there are
still many open questions about outcome including
whether SUDs actually cause or contribute to the onset of
bipolar disorder. The answers to these questions may
necessitate changes in the way both bipolar disorder and
SUD are treated. For example, certain populations may be
especially vulnerable to the onset of bipolar disorder with
substance use. It would be important to educate and
aggressively treat such at risk populations. Therefore
research addressing the casual nature of the relationship
between bipolar disorder and SUDs should be given high
priority.
In addition to outcome studies, more research examining
specific treatments in this population is needed and
should be given a high priority. Specifically, double blind
placebo controlled trials are needed to establish the effec-
tiveness of medications found to be efficacious in open
label treatments. Only with double blind studies can we
be confident in the effectiveness of the potential treat-
ments successful in open label trials. New research also
needs to be conducted on medications found to treat
either bipolar disorder or a SUD in isolation. Double-
blind placebo-controlled studies are needed to determine
if these treatments are efficacious in dual diagnoses
patients. This also raises the question of whether patients
with co-occurring SUDs should be excluded from new
clinical trials of medication for bipolar disorder. There
may be compelling reasons to exclude patients with ongo-
ing SUDs, but it might be advisable to include patients
with prior SUDs and thereby better generalize the results
to the actual patient population.
The epidemiological evidence for the extremely high rate
of co-occurring SUDs in patients with bipolar disorder
along with the outcome data suggest that neither illness
can be ignored. Therefore some level of integrated treat-
Table 1: Epidemiology studies examining the prevalence of co-occurring SUDs in bipolar disorder.
Epidemiological Study Number of subjects Lifetime prevalence of co-occurring SUDs 
in bipolar I (or combined total if type not 
specified)
Lifetime prevalence of co-
occurring SUDs in bipolar II
NESARC [2] General Population; 43,093 
subjects
58% for alcohol use disorders; 38% for 
drug use disorders
National Institutes of Mental 
Health Epidemiologic Catchment 
Area Program [5]
General Population; 20,291 
subjects
61% for any SUD 48% for any SUD
Cassidy et al. [6] 392 bipolar I patients 48.5% for alcohol abuse; 24.2% for 
cocaine abuse; 4.6% for opioid abuse; 36% 
for cannabis abuse.
McElroy et al. [7] 239 bipolar I; 49 bipolar II 36% for alcohol abuse; 10% for cocaine 
abuse; 8% for opioid abuse; 40% for 
cannabis abuse.
22% for alcohol abuse; 4% for 
cocaine abuse; 0% for opioid 
abuse; 10% for cannabis abuse.
Chengappa et al. [35] 71 bipolar I; 18 bipolar II 57.8% for alcohol abuse; 11.3% for 
cocaine abuse; 5.6% for opioid abuse; 
19.7% for cannabis abuse.
38.9% for alcohol abuse; 5.6% for 
cocaine abuse; 0% for opioid 
abuse; 5.6% for cannabis abuse.
The University of Cincinnati First-
Episode Mania Study [14, 15]
144 bipolar I 42% for alcohol abuse; 46% for cannabis 
abuse
The McLean-Harvard First-Episode 
Mania Study [9]
112 bipolar I 33% for any SUD during the index 
affective episode
Veterans Affairs (VA) Cooperative 
Study #450 [10]
328 bipolar I and II patients 
(analyzed together)
61.9% for alcohol abuse; 19.5% for 
cocaine abuse; 8.5% for opioid abuse; 
22.6% for cannabis abuseSubstance Abuse Treatment, Prevention, and Policy 2007, 2:29 http://www.substanceabusepolicy.com/content/2/1/29
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ment is needed, even if this simply means treating both
disorders separately using the best evidence possible for
each disorder. While some research suggests that certain
medications may be efficacious for both disorders, it is
still an open empirical question as to how much more
treatment can be integrated. Until more research is availa-
ble specifically targeting this population, physicians
should treat each illness separately using the most effec-
tive treatment available.
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